Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma
- 1 March 2012
- journal article
- Published by Taylor & Francis Ltd in Leukemia & Lymphoma
- Vol. 53 (9), 1820-1823
- https://doi.org/10.3109/10428194.2012.661175
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group studyLeukemia, 2011
- In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myelomaHaematologica, 2009
- Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challengesCancer Letters, 2009
- Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell LymphomaClinical Cancer Research, 2008
- Improved survival in multiple myeloma and the impact of novel therapiesBlood, 2008
- Aggresome induction by proteasome inhibitor bortezomib and α-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cellsBlood, 2006
- International uniform response criteria for multiple myelomaLeukemia, 2006
- Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90Journal of Biological Chemistry, 2005
- Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myelomaProceedings of the National Academy of Sciences of the United States of America, 2005
- CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATIONBritish Journal of Haematology, 1998